Oncology and Hematology - MedEd On The Go

Episodes 17-32 of 84

Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
MinuteCE®
Pacritinib for Myelofibrosis Across the Cytopenic Spectrum
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Improving Transfusion Independence With JAK Inhibitor Therapy
Improving Transfusion Independence With JAK Inhibitor Therapy
MinuteCE®
Improving Transfusion Independence With JAK Inhibitor Therapy
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
Managing Myelofibrosis-Associated Anemia
Managing Myelofibrosis-Associated Anemia
MinuteCE®
Managing Myelofibrosis-Associated Anemia
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit
Real-World Experience With Pacritinib in the US
Real-World Experience With Pacritinib in the US
MinuteCE®
Real-World Experience With Pacritinib in the US
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
MinuteCE®
How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment
1.00 program credit
- Gabriela Hobbs, MD
1.00 program credit
How and When to Manage Ruxolitinib Failure
How and When to Manage Ruxolitinib Failure
MinuteCE®
How and When to Manage Ruxolitinib Failure
1.00 program credit
- John Mascarenhas, MD
1.00 program credit
MinuteCE®
Tailoring JAK Inhibitor Therapy in Patients With Myelofibrosis
1.00 credit 10 episodes
- John Mascarenhas, MD
- Gabriela Hobbs, MD
1.00 credit 10 episodes
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
MinuteCE®
Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?
1.00 program credit
- John Mascarenhas, MD
- Gabriela Hobbs, MD
1.00 program credit
Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC
Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC
MinuteCE®
Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC
1.00 program credit
- Aiwu Ruth He, MD, PhD
1.00 program credit
Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC
Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC
MinuteCE®
Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC
1.00 program credit
- Ghassan K. Abou-Alfa, MD
1.00 program credit
MinuteCE®
Unresectable Hepatocellular Carcinoma: Selecting the Optimal First-Line ICI Combination
1.00 credit 10 episodes
- Aiwu Ruth He, MD, PhD
- Ghassan K. Abou-Alfa, MD
1.00 credit 10 episodes
Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models
Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models
MinuteCE®
Enhancing Outcomes in Unresectable HCC Through Integrated Multidisciplinary Care Models
1.00 program credit
- Ghassan K. Abou-Alfa, MD
- Aiwu Ruth He, MD, PhD
1.00 program credit
Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices
Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices
MinuteCE®
Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices
1.00 program credit
- Aiwu Ruth He, MD, PhD
1.00 program credit
Current Unmet Needs in the Field of Unresectable HCC
Current Unmet Needs in the Field of Unresectable HCC
MinuteCE®
Current Unmet Needs in the Field of Unresectable HCC
1.00 program credit
- Ghassan K. Abou-Alfa, MD
- Aiwu Ruth He, MD, PhD
1.00 program credit
Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
MinuteCE®
Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC
1.00 program credit
- Ghassan K. Abou-Alfa, MD
1.00 program credit
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
MinuteCE®
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
1.00 program credit
- Ghassan K. Abou-Alfa, MD
- Aiwu Ruth He, MD, PhD
1.00 program credit

2/6